Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

PICAROS - Acalabrutinibe RWE em 1L CLL na Espanha (PICAROS)

3 de novembro de 2026 atualizado por: AstraZeneca

Estudo de Coorte Não Intervencionista de Pacientes Não Tratados Anteriormente ou Intolerantes ao BTKi de Primeira Geração com Leucemia Linfocítica Crônica Descrevendo o Uso de Primeira Linha de Acalabrutinibe e Seus Resultados no Mundo Real na Espanha: o Estudo PICAROS

This is a multicenter non-interventional study (NIS) of patients with CLL treated with first-line acalabrutinib according to routine clinical practice in Spain. It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).

Visão geral do estudo

Status

Recrutamento

Condições

Descrição detalhada

This is a multicenter, non-interventional study (NIS) based on ambispective (including retrospective and/or prospective) real-world data collection of patients with CLL who received treatment with acalabrutinib for the first time in Spain.

It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).

For the cohort 1, the start of acalabrutinib treatment (index date) was prior to the first site initiation visit. For both cohorts 1 and 2, the clinical decision of starting patient on acalabrutinib has to independently occur prior to the patient inclusion into this study. Patients' eligibility for study inclusion is regardless of their current status of acalabrutinib therapy, for example, patients already deceased or discontinued therapy are still eligible to be included into this study. Patient data will be collected both retrospectively and/or prospectively up to approximately 32 months from the first site initiation visit for cohort 1, and approximately 25 months after the inclusion of the last patient in the cohort 2. For patients who received acalabrutinib therapy and have deceased, only retrospective medical chart review will be conducted.

Tipo de estudo

Observacional

Inscrição (Estimado)

315

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Andalusia
      • Almería, Andalusia, Espanha, 4009
        • Recrutamento
        • Research Site
      • Córdoba, Andalusia, Espanha, 14004
        • Recrutamento
        • Research Site
      • Granada, Andalusia, Espanha, 18014
        • Recrutamento
        • Research Site
      • Jaén, Andalusia, Espanha, 23007
        • Ativo, não recrutando
        • Research Site
      • Marbella, Andalusia, Espanha, 29603
        • Ativo, não recrutando
        • Research Site
      • Málaga, Andalusia, Espanha, 29010
        • Ativo, não recrutando
        • Research Site
      • Seville, Andalusia, Espanha, 41013
        • Recrutamento
        • Research Site
    • Aragon
      • Zaragoza, Aragon, Espanha, 50009
        • Recrutamento
        • Research Site
      • Zaragoza, Aragon, Espanha, 50009
        • Ativo, não recrutando
        • Research Site
    • Balearic Islands
      • Palma de Mallorca, Balearic Islands, Espanha, 7010
        • Ativo, não recrutando
        • Research Site
      • Palma de Mallorca, Balearic Islands, Espanha, 7198
        • Ativo, não recrutando
        • Research Site
    • Basque Country
      • Donostia / San Sebastian, Basque Country, Espanha, 20014
        • Retirado
        • Research Site
      • Galdakao, Basque Country, Espanha, 48960
        • Retirado
        • Research Site
    • Canary Islands
      • Las Palmas de Gran Canaria, Canary Islands, Espanha, 35016
        • Ativo, não recrutando
        • Research Site
      • Las Palmas de Gran Canaria, Canary Islands, Espanha, 35019
        • Ativo, não recrutando
        • Research Site
      • San Cristóbal de La Laguna, Canary Islands, Espanha, 38320
        • Recrutamento
        • Research Site
    • Cantabria
      • Santander, Cantabria, Espanha, 39008
        • Ativo, não recrutando
        • Research Site
    • Castille and León
      • Salamanca, Castille and León, Espanha, 37007
        • Ativo, não recrutando
        • Research Site
      • Segovia, Castille and León, Espanha, 40002
        • Ativo, não recrutando
        • Research Site
      • Valladolid, Castille and León, Espanha, 47003
        • Ativo, não recrutando
        • Research Site
      • Valladolid, Castille and León, Espanha, 47012
        • Ativo, não recrutando
        • Research Site
    • Castille-La Mancha
      • Guadalajara, Castille-La Mancha, Espanha, 19002
        • Recrutamento
        • Research Site
      • Toledo, Castille-La Mancha, Espanha, 45004
        • Ativo, não recrutando
        • Research Site
    • Catalonia
      • Barcelona, Catalonia, Espanha, 8003
        • Ativo, não recrutando
        • Research Site
      • Barcelona, Catalonia, Espanha, 8025
        • Ativo, não recrutando
        • Research Site
      • Barcelona, Catalonia, Espanha, 8035
        • Ativo, não recrutando
        • Research Site
      • Barcelona, Catalonia, Espanha, 8036
        • Ativo, não recrutando
        • Research Site
      • Granollers, Catalonia, Espanha, 8402
        • Ativo, não recrutando
        • Research Site
      • L'Hospitalet de Llobregat, Catalonia, Espanha, 8908
        • Ativo, não recrutando
        • Research Site
      • Lleida, Catalonia, Espanha, 25198
        • Ativo, não recrutando
        • Research Site
      • Terrassa, Catalonia, Espanha, 8221
        • Ativo, não recrutando
        • Research Site
    • Galicia
      • Ourense, Galicia, Espanha, 32005
        • Recrutamento
        • Research Site
      • Santiago de Compostela, Galicia, Espanha, 15706
        • Ativo, não recrutando
        • Research Site
      • Vigo, Galicia, Espanha, 36312
        • Recrutamento
        • Research Site
    • Madrid
      • Madrid, Madrid, Espanha, 28006
        • Recrutamento
        • Research Site
      • Madrid, Madrid, Espanha, 28031
        • Ativo, não recrutando
        • Research Site
      • Madrid, Madrid, Espanha, 28034
        • Ativo, não recrutando
        • Research Site
      • Madrid, Madrid, Espanha, 28905
        • Ativo, não recrutando
        • Research Site
      • Madrid, Madrid, Espanha, 28911
        • Ativo, não recrutando
        • Research Site
      • Madrid, Madrid, Espanha, 28040
        • Recrutamento
        • Research Site
      • Madrid, Madrid, Espanha, 28041
        • Recrutamento
        • Research Site
      • Madrid, Madrid, Espanha, 28046
        • Recrutamento
        • Research Site
      • Majadahonda, Madrid, Espanha, 28222
        • Ativo, não recrutando
        • Research Site
    • Murcia
      • El Palmar, Murcia, Espanha, 30120
        • Ativo, não recrutando
        • Research Site
      • Murcia, Murcia, Espanha, 30008
        • Recrutamento
        • Research Site
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Espanha, 33011
        • Ativo, não recrutando
        • Research Site
    • Valencia
      • Alicante, Valencia, Espanha, 3010
        • Recrutamento
        • Research Site
      • Valencia, Valencia, Espanha, 46010
        • Ativo, não recrutando
        • Research Site
      • Valencia, Valencia, Espanha, 46014
        • Ativo, não recrutando
        • Research Site
      • Valencia, Valencia, Espanha, 46026
        • Ativo, não recrutando
        • Research Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

The study aims to include approximately 315 patients in the cohort 1 and 103 patients in the cohort 2 who started acalabrutinib for the first time for the treatment of their CLL. To minimize selection biases, all patients (alive or deceased) identified on acalabrutinib will be eligible for inclusion into the study. These patients will be included from approximately 50 hospitals distributed throughout Spain.

Descrição

Inclusion Criteria:

  • Age ≥18 years old at starting acalabrutinib treatment.
  • Diagnosis of CLL.
  • Start of acalabrutinib treatment (index date) as per the CLL SmPC:
  • in treatment-naïve CLL patients or those switching in first-line between first-generation BTK inhibitor to acalabrutinib due to intolerance in absence of progression according to routine clinical practice within the year before the first site initiation visit (cohort 1).
  • in treatment-naïve CLL patients for the fixed-duration treatment combination of acalabrutinib plus venetoclax (with or without obinutuzumab) according to routine clinical practice from the EMA approval (i.e., 2 June 2025) (cohort 2).

Decision to administer acalabrutinib must be made and documented prior to inclusion into the study and must follow local clinical practice.

  • Informed consent (for alive patients).

Exclusion Criteria:

  • Enrolled in any clinical trial during acalabrutinib treatment.
  • Patients who are unable to understand the study and its questionnaires due to insufficient knowledge of the Spanish language or their health status.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: OTHER

Coortes e Intervenções

Grupo / Coorte
Cohort 1

Patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit as per routine clinical practice, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression.

Cohort 2

Patients with first-line fixed-duration acalabrutinib use with venetoclax in routine clinical practice.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).
Prazo: 24 months after treatment initiation (cohort 1).

Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).

In addition to this outcome measured in the overall cohort, it will also be assessed by the following factors:

  1. the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression),
  2. presence/absence of risk factors (i.e., del17p, TP53 mutation, and unmutated IGHV).
  3. cardiovascular comorbidities (yes/no).
24 months after treatment initiation (cohort 1).
Real-world overall response rate (rwORR) achieved until the end of the observational period for first-line fixed duration acalabrutinib therapy (cohort 2)
Prazo: From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.

rwORR (i.e., the proportion of patients that achieved complete or partial response) achieved until the end of the observational period for first-line fixed-duration acalabrutinib therapy as assessed by the treating physician (cohort 2). Complete response may include complete response, complete response with incomplete marrow recovery, or unconfirmed complete response (marrow biopsy not performed). Partial response may include partial response, or partial response with lymphocytosis. The rwORR will be assessed by the treating physician in routine clinical practice, including the use or not of the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. The end of observational period for first-line fixed-duration combinations of acalabrutinib is defined as the start date of a subsequent line therapy or study end date, whichever comes first.

From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Acalabrutinib±venetoclax doses (cohorts 1 and 2).
Prazo: At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Acalabrutinib±venetoclax doses (e.g., starting does and dose adjustments), overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In cohort 2, doses (e.g., starting dose, dose adjustments, maximum dose achieved) and reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the time to reach the maximal dose.

At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Patients with acalabrutinib±venetoclax dose adjustments (n, %), temporary interruptions (n, %), and permanent discontinuations (n, %) (cohorts 1 and 2).
Prazo: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Acalabrutinib±venetoclax dose adjustments, temporary interruptions, and permanent discontinuations, overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In patients with regimen modifications within cohort 2, the proportion of patients with these regimen modifications and the time from treatment initiation to the regimen modification within same line therapy prior to progression (e.g., treatment duration and number of cycles prior to the modification, and reason for the modification). In cohort 2, temporary interruptions, permanent discontinuations, and their reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the proportion of patients requiring dose reductions after achieving maximum dose.

From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Treatment duration in months (cohorts 1 and 2).
Prazo: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Treatment duration (cohorts 1 and 2), overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In cohort 2, also median number of completed cycles and the proportion of patients who complete 14 cycles.

Baseline patient characteristics associated with treatment duration in multivariate analyses, overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib (cohort 1).
Prazo: From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).

Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1).

The PDC will be based on data available on acalabrutinib treatment in pharmacy records, and defined as the percentage of days a patient has the medication available in a given period of time:

PDC (%)=(No.days covered)/(No.days of interest)×100

From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).
TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause) (cohorts 1 and 2).
Prazo: From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause [i.e. deaths are not censored]), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause) (cohorts 1 and 2).
Prazo: From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation; that are considered serious during acalabrutinib±venetoclax treatment; and events of clinical interest (cohorts 1 and 2).
Prazo: From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation.

Adverse events that are considered serious (including fatal events) during acalabrutinib±venetoclax treatment, globally and treatment related (when available).

Events of clinical interest (atrial fibrillation, hypertension, bleeding, infections, ventricular arrhythmias, hepatotoxicity, secondary primary malignancies, cytopenia, and pneumonitis) during acalabrutinib treatment, globally and treatment related (when available).

They will be described overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

11 de julho de 2023

Conclusão Primária (Estimado)

31 de março de 2029

Conclusão do estudo (Estimado)

31 de março de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

29 de junho de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de agosto de 2023

Primeira postagem (Real)

21 de agosto de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

4 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

3 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • D8221R00003

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Prazo de Compartilhamento de IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Critérios de acesso de compartilhamento IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .